Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Five9 Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.1 (market cap $39.89B), while Five9 Inc trades at $26.09 (market cap $1.95B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 20.5× Five9 Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FIVN | |
|---|---|---|
Market Cap | $39.89B | $1.95B |
Sector | Health | Technology |
52-Week High | $491.22 | $29.16 |
52-Week Low | $278.09 | $13.61 |
Enterprise Value | $38.15B | $2.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Five9 (FIVN) trades at $25.42, up 1.97% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $779M in 2022 to $1.15B in 2025 and a shift to profitability. Recent Q1 2026 earnings beat expectations, and the stock benefits from strong analyst support (61% buy rating) and a $27 consensus price target. However, negative net cash flow and ongoing legal scrutiny present near-term headwinds.
The outlook remains positive given consistent earnings beats and strategic leadership appointments, but risks include insider selling and litigation concerns. Upside potential exists if the company maintains its growth trajectory and addresses cash flow challenges, making it a watch for growth-oriented investors despite volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
